Recent trends in systemic psoriasis treatment costs

Vivianne Beyer, Stephen Wolverton

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

Objectives: To analyze the current total cost of systemic therapy for psoriasis and to compare annual trends in the cost of both generic and brand-name therapies with trends in the Consumer Price Index-Urban since 2000. Design: A cost model was developed that includes costs for prescription drugs, office visits, and suggested laboratory tests and monitoring procedures. Annual trends in psoriasis drug costs from 2000 through 2008 were analyzed by calculating the percentage change in the average wholesale price from the previous year; these values were compared with changes in the yearly Consumer Price Index-Urban values. Setting: The United States. Main Outcome Measures: Total annual costs for systemic psoriasis therapies and trends in cost compared with the trends in Consumer Price Index-Urban values (equivalent to inflation). Results: Current total annual costs for systemic psoriasis therapies ranged from $1197 (methotrexate) to $27 577 (alefacept, two 12-week courses). Trends in the average wholesale price of brand-name psoriasis therapies from 2000 through 2008 demonstrate an average increase of 66% (range, -24% to +316%); thus, costs of several brand-name psoriasis drugs greatly outpaced the rates of inflation for all items and all prescription drugs. Conclusions: Despite the higher monitoring costs associated with traditional systemic therapies, annual costs of biologics exceed those of other available therapies. Current trends demonstrate that systemic psoriasis therapy costs are increasing at a much higher rate compared with general inflation.

Original languageEnglish
Pages (from-to)46-54
Number of pages9
JournalArchives of Dermatology
Volume146
Issue number1
DOIs
StatePublished - Jan 2010

Fingerprint

Psoriasis
Health Care Costs
Costs and Cost Analysis
Economic Inflation
Names
Prescription Drugs
Economics
Therapeutics
Office Visits
Drug Costs
Biological Products
Methotrexate
Outcome Assessment (Health Care)

ASJC Scopus subject areas

  • Dermatology

Cite this

Recent trends in systemic psoriasis treatment costs. / Beyer, Vivianne; Wolverton, Stephen.

In: Archives of Dermatology, Vol. 146, No. 1, 01.2010, p. 46-54.

Research output: Contribution to journalArticle

@article{28dfd7dcad784c88a7b29c5be8436726,
title = "Recent trends in systemic psoriasis treatment costs",
abstract = "Objectives: To analyze the current total cost of systemic therapy for psoriasis and to compare annual trends in the cost of both generic and brand-name therapies with trends in the Consumer Price Index-Urban since 2000. Design: A cost model was developed that includes costs for prescription drugs, office visits, and suggested laboratory tests and monitoring procedures. Annual trends in psoriasis drug costs from 2000 through 2008 were analyzed by calculating the percentage change in the average wholesale price from the previous year; these values were compared with changes in the yearly Consumer Price Index-Urban values. Setting: The United States. Main Outcome Measures: Total annual costs for systemic psoriasis therapies and trends in cost compared with the trends in Consumer Price Index-Urban values (equivalent to inflation). Results: Current total annual costs for systemic psoriasis therapies ranged from $1197 (methotrexate) to $27 577 (alefacept, two 12-week courses). Trends in the average wholesale price of brand-name psoriasis therapies from 2000 through 2008 demonstrate an average increase of 66{\%} (range, -24{\%} to +316{\%}); thus, costs of several brand-name psoriasis drugs greatly outpaced the rates of inflation for all items and all prescription drugs. Conclusions: Despite the higher monitoring costs associated with traditional systemic therapies, annual costs of biologics exceed those of other available therapies. Current trends demonstrate that systemic psoriasis therapy costs are increasing at a much higher rate compared with general inflation.",
author = "Vivianne Beyer and Stephen Wolverton",
year = "2010",
month = "1",
doi = "10.1001/archdermatol.2009.319",
language = "English",
volume = "146",
pages = "46--54",
journal = "JAMA Dermatology",
issn = "2168-6068",
publisher = "American Medical Association",
number = "1",

}

TY - JOUR

T1 - Recent trends in systemic psoriasis treatment costs

AU - Beyer, Vivianne

AU - Wolverton, Stephen

PY - 2010/1

Y1 - 2010/1

N2 - Objectives: To analyze the current total cost of systemic therapy for psoriasis and to compare annual trends in the cost of both generic and brand-name therapies with trends in the Consumer Price Index-Urban since 2000. Design: A cost model was developed that includes costs for prescription drugs, office visits, and suggested laboratory tests and monitoring procedures. Annual trends in psoriasis drug costs from 2000 through 2008 were analyzed by calculating the percentage change in the average wholesale price from the previous year; these values were compared with changes in the yearly Consumer Price Index-Urban values. Setting: The United States. Main Outcome Measures: Total annual costs for systemic psoriasis therapies and trends in cost compared with the trends in Consumer Price Index-Urban values (equivalent to inflation). Results: Current total annual costs for systemic psoriasis therapies ranged from $1197 (methotrexate) to $27 577 (alefacept, two 12-week courses). Trends in the average wholesale price of brand-name psoriasis therapies from 2000 through 2008 demonstrate an average increase of 66% (range, -24% to +316%); thus, costs of several brand-name psoriasis drugs greatly outpaced the rates of inflation for all items and all prescription drugs. Conclusions: Despite the higher monitoring costs associated with traditional systemic therapies, annual costs of biologics exceed those of other available therapies. Current trends demonstrate that systemic psoriasis therapy costs are increasing at a much higher rate compared with general inflation.

AB - Objectives: To analyze the current total cost of systemic therapy for psoriasis and to compare annual trends in the cost of both generic and brand-name therapies with trends in the Consumer Price Index-Urban since 2000. Design: A cost model was developed that includes costs for prescription drugs, office visits, and suggested laboratory tests and monitoring procedures. Annual trends in psoriasis drug costs from 2000 through 2008 were analyzed by calculating the percentage change in the average wholesale price from the previous year; these values were compared with changes in the yearly Consumer Price Index-Urban values. Setting: The United States. Main Outcome Measures: Total annual costs for systemic psoriasis therapies and trends in cost compared with the trends in Consumer Price Index-Urban values (equivalent to inflation). Results: Current total annual costs for systemic psoriasis therapies ranged from $1197 (methotrexate) to $27 577 (alefacept, two 12-week courses). Trends in the average wholesale price of brand-name psoriasis therapies from 2000 through 2008 demonstrate an average increase of 66% (range, -24% to +316%); thus, costs of several brand-name psoriasis drugs greatly outpaced the rates of inflation for all items and all prescription drugs. Conclusions: Despite the higher monitoring costs associated with traditional systemic therapies, annual costs of biologics exceed those of other available therapies. Current trends demonstrate that systemic psoriasis therapy costs are increasing at a much higher rate compared with general inflation.

UR - http://www.scopus.com/inward/record.url?scp=74549221523&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74549221523&partnerID=8YFLogxK

U2 - 10.1001/archdermatol.2009.319

DO - 10.1001/archdermatol.2009.319

M3 - Article

C2 - 20083692

AN - SCOPUS:74549221523

VL - 146

SP - 46

EP - 54

JO - JAMA Dermatology

JF - JAMA Dermatology

SN - 2168-6068

IS - 1

ER -